Search Results - "BOSS, Carol"
-
1
Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
Published in Journal of clinical oncology (10-12-2010)“…Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and progression to leukemia. Clinical and experimental evidence suggests an…”
Get full text
Journal Article -
2
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study
Published in Haematologica (Roma) (01-03-2009)“…1 Hematology Branch and 2 Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA…”
Get full text
Journal Article -
3
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Published in Haematologica (Roma) (01-03-2011)“…We previously showed that vaccination with one dose of PR1 and WT1 peptides induces transient anti-leukemia immunity. We hypothesized that maintenance of a…”
Get full text
Journal Article -
4
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
Published in Haematologica (Roma) (01-09-2009)“…1 Hematology Branch, NHLBI 2 Office of Biostatistics Research, NHLBI 3 Department of Pharmacy, Clinical Center 4 Flow Cytometry Core Facility, NHLBI 5…”
Get full text
Journal Article -
5
Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura
Published in Haematologica (Roma) (01-02-2006)“…We administered daclizumab, a humanized monoclonal anti-interleukin-2 receptor (IL-2R) antibody, to 11 patients with corticosteroid-refractory autoimmune…”
Get full text
Journal Article -
6
Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer
Published in Journal of clinical oncology (01-02-2001)“…To determine the feasibility of an organ preservation regimen consisting of infusional paclitaxel administered concurrently with radiotherapy to patients with…”
Get full text
Journal Article -
7
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Published in Blood (01-01-2008)“…We describe the safety and immunogenicity of a combined vaccine of 2 leukemia-associated antigenic peptides, PR1 and WT1. Eight patients with myeloid…”
Get full text
Journal Article -
8
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers
Published in British journal of haematology (01-04-2011)“…Summary This study evaluated the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Three cohorts of six…”
Get full text
Journal Article -
9
The Response to Repeated Vaccination with PR1 and WT1 Peptides Admixed in Montanide Adjuvant Is Transient and Fails to Induce Sustained Anti-Leukemia Responses in Patients with Myeloid Malignancies
Published in Blood (20-11-2009)“…Abstract 4096 Poster Board III-1031 We previously demonstrated the immunogenicity of a combined vaccine approach employing two leukemia-associated antigenic…”
Get full text
Journal Article -
10
Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia
Published in Blood (15-11-2003)“…In contrast to severe aplastic anemia (sAA), the appropriate management of patients with moderate pancytopenia is unclear. In this study, we examined the…”
Get full text
Journal Article -
11
Allografts Selectively Photodepleted of GvHD Causing T Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve Disease Control After HLA-Matched Sibling Transplantations
Published in Blood (20-11-2009)“…Abstract 515 We established a highly efficient GMP-grade, ex-vivo selective allodepletion process where host-activated donor T cells are eliminated based on…”
Get full text
Journal Article -
12
Selective Allodepletion by TH9402-Mediated Photosensitization Results in Early Full Donor T Cell Reconstitution in the Absence of High-Grade, Acute GvHD and Is Associated with Favorable Outcome after HLA Matched Sibling SCT for Hematologic Malignancies
Published in Blood (16-11-2008)“…Selective allodepletion (SD) is a strategy to eliminate host-reactive donor T-cells from allografts to prevent graft versus host disease (GvHD) while…”
Get full text
Journal Article -
13
Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies
Published in Blood (16-11-2007)“…The graft-versus-leukemia (GVL) effect following allogeneic stem cell transplantation (SCT) is evidence that T lymphocytes can eradicate leukemia. The…”
Get full text
Journal Article -
14
A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers
Published in Blood (16-11-2007)“…Background: AMD3100 (AMD or plerixafor) inhibits the binding of SDF-1 to its cognate receptor CXCR4 resulting in the rapid mobilization of CD34+ hematopoietic…”
Get full text
Journal Article -
15
Immunosuppression for Myelodysplastic Syndrome: Association between a Score Based on Presenting Features and Long-Term Survival
Published in Blood (16-11-2004)“…Immunosuppressive therapy (IST) can improve cytopenias in selected patients with myelodysplastic syndrome (MDS). Between 1998 and 2004, 133 patients with MDS…”
Get full text
Journal Article -
16
Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome
Published in Biology of blood and marrow transplantation (01-08-2005)“…Stem cell transplantation for myelodysplastic syndrome (MDS) is characterized by high transplant-related mortality (TRM), especially in older patients and…”
Get full text
Journal Article -
17
Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10
Published in Archives of dermatology (1960) (01-10-2002)“…In several open-label studies, recombinant human interleukin 10 (rhIL-10), a type 2 anti-inflammatory cytokine, has been reported to improve psoriasis, a…”
Get more information
Journal Article -
18
-
19